Related Experiment Video
Updated: Sep 28, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer
Meenu Walia1, Manish K Singhal2, Mangesh S Kamle3
1Department of Medical Oncology, Max Super Specialty Hospital, Patparganj, New Delhi, India.
Abstract:
Evidence from several studies has shown improved progression-free survival (PFS) with first- or second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) compared with chemotherapy for advanced NSCLC patients. But resistance to first or second-generation TKI therapies after 9 to 12 months of treatment initiation is a concern. Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFRm (epidermal growth factor receptor mutated) and EGFR T790M and has demonstrated efficacy in NSCLC central nervous system (CNS) metastases. Trials have reported significantly longer PFS and higher median duration of response with osimertinib compared with first-generation EGFR-TKIs (erlotinib, gefitinib) and chemotherapy, respectively. And relatively lower rates of discontinuation due to adverse events (AEs). Significant improvement in overall survival was also observed when used as first-line treatment. Because EGFR-mutated tumors are highly dependent on EGFR signaling, optimal sequence of available TKIs - erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib - is necessary. The sequencing of EGFR-TKIs has changed over the past decade and depends on factors such as expected efficacy, CNS activity, tolerability, and options available after progression. Third-generation TKI may be the preferred first-line treatment because patients may not opt for or die before the start of second-line therapy, and it is difficult to predict which patients will eventually develop T790M mutation. The favorable tolerability profile alongside a longer time to disease progression makes osimertinib a preferred first-line treatment. Though clinical practice guidelines do not provide clear consensus on the most preferred EGFR-TKI, recent updates recommend osimertinib as a first-line treatment for advanced NSCLC patients. Also, improved patient selection incorporating clinical and molecular characteristics will help translate to better survival outcomes and improved quality of life. This review aims to determine the optimal sequence of administration of the EGFR-TKIs considering toxicity, quality of life, and survival outcomes among advanced NSCLC patients.
Insights
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), like osimertinib, offer improved progression-free survival and tolerability over older TKIs and chemotherapy for advanced non-small cell lung cancer (NSCLC). Optimal sequencing is key for better outcomes.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- First- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) improve progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) but are limited by resistance.
- Resistance to first- or second-generation EGFR-TKIs typically emerges after 9-12 months of treatment.
Purpose of the Study:
- To review the optimal sequencing of EGFR-TKIs for advanced NSCLC, considering efficacy, central nervous system (CNS) activity, tolerability, and post-progression options.
- To evaluate the role of third-generation EGFR-TKIs, specifically osimertinib, in first-line treatment for advanced NSCLC.
Main Methods:
- Systematic review of clinical trials and practice guidelines on EGFR-TKI sequencing in advanced NSCLC.
- Analysis of efficacy, safety, and quality-of-life data for first-, second-, and third-generation EGFR-TKIs.
Main Results:
- Osimertinib demonstrates superior PFS and duration of response compared to first-generation EGFR-TKIs and chemotherapy, with lower adverse event discontinuation rates.
- Osimertinib shows significant overall survival improvement as a first-line treatment and efficacy in NSCLC with CNS metastases.
- Third-generation TKIs may be preferred first-line due to challenges in predicting T790M mutation development and potential patient mortality before second-line therapy.
Conclusions:
- Osimertinib's favorable tolerability and prolonged time to disease progression support its use as a preferred first-line treatment for advanced NSCLC.
- While clinical guidelines lack consensus, recent updates recommend osimertinib for first-line therapy, emphasizing improved patient selection for better survival and quality of life.
